Court records or major news outlets

U.S. House Sets 2032 Deadline for Decoupling with WuXi AppTec, Other Chinese Biotechs

May 10, 2024, 05:30 PM

The U.S. House of Representatives has revised the Biosecure Act, setting a new 2032 decoupling deadline for American drugmakers to sever ties with Chinese biotechnology firms such as WuXi AppTec and WuXi Biologics. Originally, the bill proposed a more rapid decoupling from Chinese biotechs, which raised concerns among stakeholders about potential negative impacts on patients and biopharmaceutical companies. A survey by @IAmBiotech highlighted these concerns. Additionally, WuXi AppTec has been actively contesting the claims made in the anti-China biotech bills, asserting its role in bolstering U.S. biomanufacturing.